Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetrahydrocannabivarin + tetrahydrocannabinol is a combination of two naturally occurring cannabinoids found in cannabis plants: tetrahydrocannabivarin (THCV) and tetrahydrocannabinol (THC). THCV is structurally similar to THC but possesses a shorter side chain, which results in distinct pharmacological properties. THCV acts primarily as a cannabinoid-1 (CB1) receptor antagonist and a cannabinoid-2 (CB2) receptor partial agonist, contrasting with THC's partial agonist activity at both receptors. THCV has been associated with appetite suppression, improved glycemic control, and potential neuroprotective benefits. THC, the primary psychoactive component of cannabis, activates CB1 and CB2 receptors and is known for its effects on mood, appetite stimulation, and pain modulation. The combination is under investigation for metabolic disorders, neuropathic pain, and other indications, but is not currently approved as a pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetrahydrocannabivarin + tetrahydrocannabinol.